Skip to main content
SpringerLink
Log in

Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Introduction

Hairy cell leukemia (HCL) is an uncommon B cell lymphoproliferative disorder. The object of the present audit was to assess whether the investigation and management of HCL in University College Hospital Galway (UCHG) complies with the British Committee for Standards in Haematology (BCSH) guidelines.

Methods

Following a review of the records in our Haematology Department, 18 cases of HCL were identified between January 2006 and October 2014.

Results

Blood film examination had been performed in all cases. Flow cytometry of liquid material had been undertaken in 89 % (n = 16) of cases, of which only 31 % (n = 5) included all four hairy cell panel markers (CD11c, CD25, CD103, CD123). Although all initial trephine biopsies included CD20, none analyzed DBA44. Only 65 % (n = 11) of treated patients had a post-treatment bone marrow biopsy preformed.

Conclusion

This audit highlights areas of improvement in the diagnosis and management of HCL in UCHG, which do not currently adhere to the BCSH recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jones G et al (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. www.bcshguidelines.com

  2. Gerver MR (2010) How I treat hairy cell leukemia. Blood 115(1):21–28

    Article  Google Scholar 

  3. Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918–1926

    CAS  PubMed  Google Scholar 

  4. Maloisel F, Benboubker L, Gardembas M et al (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia 17(1):45–51

    Article  CAS  PubMed  Google Scholar 

  5. Catovsky D, On behalf of the Clinical Task Force of the British Committee for Standards in Haematology (2000) Hairy cell leukaemia. Guidelines on diagnosis and therapy. http://www.bcshguidelines.com/documents/hairy_cell_leukaemia_2000.pdf

  6. Ravandi F, Jorgensen JL, O’Brien SM et al (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658–4662

    Article  CAS  PubMed  Google Scholar 

  7. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S et al (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 130(3):374–377

    PubMed  Google Scholar 

  8. Else M, Dearden CE, Catovsky D (2015) Long term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol 28(4):217–229

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology Department, Galway University Hospital, Galway, Ireland

    K. Velazquez-Kennedy, C. Crowe, B. Craven, J. Walsh, C. Prendergast & J. Krawczyk

Authors
  1. K. Velazquez-Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Crowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Craven
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Prendergast
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Krawczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Velazquez-Kennedy.

Ethics declarations

Conflict of interest

Dr Kyra Velazquez-Kennedy declares that she has no conflict of interest; Dr Catherine Crowe declares that she has no conflict of interest; Dr Brian Craven declares that he has no conflict of interest; Dr Joseph Walsh declares that he has no conflict of interest, Dr Ciaran Prendergast declares that he has no conflict of interest; Janusz Krawczyk declares that he has no conflict of interest.

Ethical approval

This article is a clinical audit, and as such it does not contain any studies with human participants or animals performed by any of the authors. Due to the nature of this clinical audit, which was designed to improve the quality of care provided to patients in our center, implied consent was considered as sufficient from the patient cohort (Refer to: Data Protection Guidelines on research in the Health Sector. An Coimisinéir Cosanta Sonraí-Data Protection Commisioner).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Velazquez-Kennedy, K., Crowe, C., Craven, B. et al. Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway. Ir J Med Sci 186, 345–347 (2017). https://doi.org/10.1007/s11845-016-1460-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-016-1460-4

Keywords

Search

Navigation